Free tool
FAERS Monitor: Optison
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020899 or its brand name (Optison, Albumin Human). Reports on generic versions are filed under their own applications.
Reports
141
Serious
46
33% of reports
Hospitalization
17
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness15
- back pain13
- chest pain12
- drug ineffective12
- no adverse event12
- nausea11
- dyspnoea9
- feeling hot7
- headache7
- flushing6
- off label use6
- product quality issue6
- tremor6
- vomiting6
- anaphylactic reaction5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 14 |
| 2015 | 7 |
| 2016 | 10 |
| 2017 | 6 |
| 2018 | 11 |
| 2019 | 7 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 11 |
| 2023 | 12 |
| 2024 | 15 |
| 2025 | 13 |
| 2026 | 20 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,018 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| feeling hotSignal | 7 | 17.0 | 8.3 | 90 |
| anaphylactic reactionSignal | 5 | 13.5 | 5.7 | 46 |
| no adverse eventSignal | 12 | 9.9 | 5.8 | 88 |
| chest painSignal | 12 | 9.7 | 5.6 | 86 |
| flushingSignal | 6 | 8.8 | 4.0 | 34 |
| back painSignal | 13 | 8.3 | 5.0 | 78 |
| product quality issueSignal | 6 | 6.6 | 3.0 | 23 |
| tremorSignal | 6 | 5.4 | 2.5 | 17 |
| dizzinessSignal | 15 | 4.5 | 2.8 | 38 |
| dyspnoeaSignal | 9 | 2.4 | 1.3 | 6 |
| nauseaSignal | 11 | 2.1 | 1.2 | 5 |
| vomiting | 6 | 1.9 | 0.9 | 2 |
| headache | 7 | 1.7 | 0.8 | 1 |
| drug ineffective | 12 | 1.4 | 0.8 | 1 |
| off label use | 6 | 1.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.